The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Praluent partners Sanofi and Regeneron have been battling for market share against Amgen’s Repatha in the PCSK9 class of cholesterol drugs, including by recently lowering their price. Now, the ...
European regulators have approved a new indication for Regeneron and Sanofi’s Praluent, allowing its use to cut cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD).
Regeneron Pharmaceuticals, Inc. REGN announced that the FDA extended the approval of the cholesterol drug Praluent’s (alirocumab) label. The regulatory body approved the drug as an adjunct to diet and ...
Regeneron Pharmaceuticals, Inc. REGN announced that the European Commission (EC) has approved a label expansion of its PCSK9 inhibitor, Praluent. The drug’s label has been expanded to reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results